<DOC>
	<DOCNO>NCT02571530</DOCNO>
	<brief_summary>The purpose study evaluate safety administer single dose trastuzumab artery treatment brain metastasis ( e ) HER2/neu positive breast cancer . This study try determine best tolerate single dosage trastuzumab administer artery gradually increase dosage give participant study progress . Early participant receive dosage 1 mg/kg . As participant enroll study , single dosage increase designated level 8 mg/kg , 's determine safe increase . Trastuzumab type antibody , protein use body 's immune system fight pathogens bacteria virus . This antibody bind cell receptor know HER2/neu tyrosine kinase receptor . These receptor express certain cancer subtypes breast cancer . By block signal HER2/neu receptor , trastuzumab slow stop over-expression HER2/neu protein . Over-expression HER2/neu show play role development progression certain type breast cancer . Therefore , slow stop expression HER2/neu , investigator hope slow stop growth metastasis ( e ) increase responsiveness therapy .</brief_summary>
	<brief_title>Super-selective Intra-arterial Cerebral Infusion Trastuzumab Treatment Cerebral Metastases HER2/Neu Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Male female patient 18 year age old 2 . Karnofsky Performance Status ( KPS ) 70 high 3 . Capable give informed consent acceptable surrogate capable give consent subject 's behalf 4 . Have document history HER2/neu positive breast cancer 3+ immunohistochemical stain positive fluorescent insitu hybridization ( FISH ) chromogenic insitu hybridization ( CISH ) evidence parenchymal metastatic tumor ( ) brain imaging study . 5 . Adequate labs procedure trastuzumab , include limited White Blood Count ( WBC ) , Hemoglobin , Hematocrit , Platelet Count , Prothrombin Time ( PT ) , International Normalized Ratio ( INR ) , Sodium , Potassium , Chloride , Glucose , Blood Urea Nitrogen ( BUN ) , Serum Creatinine ( CR ) 1 . Age le 18 year 2 . KPS less 70 3 . Brain metastasis without history HER2/neu positive breast cancer 4 . Leptomeningeal dissemination brain metastases 5 . Pregnancy refusal use contraception 3 month period 7 month period Intraarterial ( IA ) trastuzumab administration 6 . Prior administration intraarterial trastuzumab 7 . Subjects inadequate baseline Left Ventricular Ejection Fraction ( LVEF ) 8 . Subjects history infusion reaction trastuzumab 9 . Subjects blood brain barrier ( BBB ) disruption mannitol within 48 hour 10 . Subjects evidence midline shift herniation 11 . Subjects resectable brain metastasis whose cerebral tumor amenable stereotactic radiosurgery 12 . Subjects progress therapy brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>